Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NEOGENOMICS INCNEO · Entity 2096 | General Counsel | March 01, 2021 | March 04, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NEOGENOMICS INC
Report date March 01, 2021 · Filed March 04, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 60,643 |
Ending reported balance
After 2021-03-02 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2021-03-01 · Tax withholding · Disposed 212 · Balance 56,514 F1: Shares surrendered to NeoGenomics Inc. for retirement to satisfy the tax obligations in connection with the March 1, 2021 vesting of restricted stock. Row 2 · 2021-03-02 · Tax withholding · Disposed 216 · Balance 56,298 F2: Shares surrendered to NeoGenomics Inc. for retirement to satisfy the tax obligations in connection with the March 2, 2021 vesting of restricted stock. Row 3 · 2021-03-02 · Grant · Acquired 4,345 · Balance 60,643 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $53.17 · Expires 2028-03-02 | Direct | 24,619 |
Reported balance
After 2021-03-02 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2021-03-02 · Grant · Acquired 24,619 · Balance 24,619 F7: On March 2, 2021, Ms. Pedulla was granted 24,619 stock options. These options vest ratably over the first four anniversary dates of the grant date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.52 · Expires 2022-04-28 | Direct | 25,000 |
Reported balance
Holding disclosure · report date 2021-03-01 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 25,000 F3: On April 28, 2017, Ms. Pedulla was granted 75,000 stock options. These options vested ratably over the first three anniversary dates of the grant date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.03 · Expires 2023-02-26 | Direct | 48,334 |
Reported balance
Holding disclosure · report date 2021-03-01 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 48,334 F4: On January 26, 2018, Ms. Pedulla was granted 72,500 stock options. These options vested ratably over the first three anniversary dates of the grant date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.60 · Expires 2024-03-01 | Direct | 17,496 |
Reported balance
Holding disclosure · report date 2021-03-01 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 17,496 F5: On March 1, 2019, Ms. Pedulla was granted 17,496 stock options. These options vest ratably over the first four anniversary dates of the grant date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.33 · Expires 2027-03-02 | Direct | 18,757 |
Reported balance
Holding disclosure · report date 2021-03-01 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 18,757 F6: On March 2, 2020, Ms. Pedulla was granted 18,757 stock options. These options vest ratably over the first four anniversary dates of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares surrendered to NeoGenomics Inc. for retirement to satisfy the tax obligations in connection with the March 1, 2021 vesting of restricted stock.
F2: Shares surrendered to NeoGenomics Inc. for retirement to satisfy the tax obligations in connection with the March 2, 2021 vesting of restricted stock.
F3: On April 28, 2017, Ms. Pedulla was granted 75,000 stock options. These options vested ratably over the first three anniversary dates of the grant date.
F4: On January 26, 2018, Ms. Pedulla was granted 72,500 stock options. These options vested ratably over the first three anniversary dates of the grant date.
F5: On March 1, 2019, Ms. Pedulla was granted 17,496 stock options. These options vest ratably over the first four anniversary dates of the grant date.
F6: On March 2, 2020, Ms. Pedulla was granted 18,757 stock options. These options vest ratably over the first four anniversary dates of the grant date.
F7: On March 2, 2021, Ms. Pedulla was granted 24,619 stock options. These options vest ratably over the first four anniversary dates of the grant date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Conformis Inc
Report date September 05, 2023 · Filed September 05, 2023
Section 16 reporting ended · disclosed 2023-09-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-09-05 transaction · row 1
1 source rowRow 1 · 2023-09-05 · Disposition to issuer · Disposed 18,000 · Balance 0 F1: The reported securities were disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 22, 2023, by and among Issuer, restor3d, Inc., a Delaware corporation ("restor3d"), and Cona Merger Sub Inc., a Delaware corporation and a wholly owned subsidiary of restor3d ("Merger Sub"). Immediately prior to effectiveness of the merger, each outstanding share of restricted stock vested in full. Upon effectiveness of the merger, in exchange for each share of Common Stock, the reporting person received $2.27 in cash, without interest and less applicable withholding taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities were disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 22, 2023, by and among Issuer, restor3d, Inc., a Delaware corporation ("restor3d"), and Cona Merger Sub Inc., a Delaware corporation and a wholly owned subsidiary of restor3d ("Merger Sub"). Immediately prior to effectiveness of the merger, each outstanding share of restricted stock vested in full. Upon effectiveness of the merger, in exchange for each share of Common Stock, the reporting person received $2.27 in cash, without interest and less applicable withholding taxes.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 05, 2023 Filed Sep 5, 2023 06:13 UTC | Conformis Inc CFMS · Entity 109987 | Disposition to issuerCommon Stock | 18,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-23-042502 · form4.xml · nonDerivative · entry 1 Pedulla Denise E · CIK 0001804602 · FORMER CLO & SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: The reported securities were disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 22, 2023, by and among Issuer, restor3d, Inc., a Delaware corporation ("restor3d"), and Cona Merger Sub Inc., a Delaware corporation and a wholly owned subsidiary of restor3d ("Merger Sub"). Immediately prior to effectiveness of the merger, each outstanding share of restricted stock vested in full. Upon effectiveness of the merger, in exchange for each share of Common Stock, the reporting person received $2.27 in cash, without interest and less applicable withholding taxes. Read SEC document |
| March 14, 2022 Filed Mar 23, 2022 16:22 UTC | Conformis Inc CFMS · Entity 109987 | GrantStock Option (right to buy) · Derivative | 450,000 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0001305773-22-000037 · wf-form4_164806691657223.xml · derivative · entry 2 Pedulla Denise E · CIK 0001804602 · CLO & SECRETARY 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 450,000 Underlying: Common Stock · 450,000 shares Expires 2032-03-14 F2 · shares: Represents an inducement grant award of options to the Reporting Person in connection with her appointment as CLO and Secretary. The option to purchase an aggregate of 450,000 shares of Issuer's common stock vests over eight years, with the following schedule: 8%, 10%, 15%, 20%, 20%, 15%, 8% and 4% of the total number of shares underlying the option vesting on each one-year anniversary of the grant date, subject to the Reporting Person's continued service as an employee of Conformis through the applicable vesting dates, and are subject to the certain forfeiture provisions. F2 · derivative.exercise_date: Represents an inducement grant award of options to the Reporting Person in connection with her appointment as CLO and Secretary. The option to purchase an aggregate of 450,000 shares of Issuer's common stock vests over eight years, with the following schedule: 8%, 10%, 15%, 20%, 20%, 15%, 8% and 4% of the total number of shares underlying the option vesting on each one-year anniversary of the grant date, subject to the Reporting Person's continued service as an employee of Conformis through the applicable vesting dates, and are subject to the certain forfeiture provisions. Read SEC document |
| March 14, 2022 Filed Mar 23, 2022 16:22 UTC | Conformis Inc CFMS · Entity 109987 | GrantCommon Stock | 450,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001305773-22-000037 · wf-form4_164806691657223.xml · nonDerivative · entry 1 Pedulla Denise E · CIK 0001804602 · CLO & SECRETARY 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 450,000 F1 · shares: Represents an inducement grant award of restricted stock units to the Reporting Person in connection with her appointment as CLO and Secretary. The restricted stock units vest over eight years, with the following schedule: 8%, 10%, 15%, 20%, 20%, 15%, 8% and 4% of the total number of shares vesting on each one-year anniversary of the grant date, subject to the Reporting Person's continued service as an employee of Conformis through the applicable vesting dates, and are subject to certain forfeiture provisions. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 01:17 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantStock Option (Right to Buy) · Derivative | 24,619 | $53.17 Strike: $53.17 | $1,308,992.23 |
DisclosureSEC source: 0001077183-21-000083 · wf-form4_161482066513083.xml · derivative · entry 8 Pedulla Denise E · CIK 0001804602 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,619 Underlying: Common Stock · 24,619 shares Expires 2028-03-02 F7 · derivative.exercise_date: On March 2, 2021, Ms. Pedulla was granted 24,619 stock options. These options vest ratably over the first four anniversary dates of the grant date. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 01:17 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantCommon Stock | 4,345 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-21-000083 · wf-form4_161482066513083.xml · nonDerivative · entry 3 Pedulla Denise E · CIK 0001804602 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,643 Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 01:17 UTC | NEOGENOMICS INC NEO · Entity 2096 | Tax withholdingCommon Stock | 216 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-21-000083 · wf-form4_161482066513083.xml · nonDerivative · entry 2 Pedulla Denise E · CIK 0001804602 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,298 F2 · shares: Shares surrendered to NeoGenomics Inc. for retirement to satisfy the tax obligations in connection with the March 2, 2021 vesting of restricted stock. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 01:17 UTC | NEOGENOMICS INC NEO · Entity 2096 | Tax withholdingCommon Stock | 212 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-21-000083 · wf-form4_161482066513083.xml · nonDerivative · entry 1 Pedulla Denise E · CIK 0001804602 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,514 F1 · shares: Shares surrendered to NeoGenomics Inc. for retirement to satisfy the tax obligations in connection with the March 1, 2021 vesting of restricted stock. Read SEC document |
| November 10, 2020 Filed Nov 12, 2020 23:00 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $7.85 | $0.00 |
DisclosureSEC source: 0001077183-20-000209 · wf-form4_160522200451410.xml · derivative · entry 3 Pedulla Denise E · CIK 0001804602 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2020-12-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: On December 8, 2015, Ms. Pedulla was granted 60,000 stock options. These options vested ratably over the first four anniversary dates of the grant date. Read SEC document |
| November 10, 2020 Filed Nov 12, 2020 23:00 UTC | NEOGENOMICS INC NEO · Entity 2096 | SaleCommon Stock | 2,262 | $42.00 | $95,004.00 |
DisclosureSEC source: 0001077183-20-000209 · wf-form4_160522200451410.xml · nonDerivative · entry 2 Pedulla Denise E · CIK 0001804602 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,726 Read SEC document |
| November 10, 2020 Filed Nov 12, 2020 23:00 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionCommon Stock | 15,000 | $7.85 | $117,750.00 |
DisclosureSEC source: 0001077183-20-000209 · wf-form4_160522200451410.xml · nonDerivative · entry 1 Pedulla Denise E · CIK 0001804602 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,988 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 01:16 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantCommon Stock · Derivative | 18,757 | $28.33 Strike: $28.33 | $531,385.81 |
DisclosureSEC source: 0001077183-20-000039 · wf-form4_158328455458567.xml · derivative · entry 6 Pedulla Denise E · CIK 0001804602 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,757 Underlying: Common Stock · 18,757 shares Expires 2027-03-02 F5 · derivative.exercise_date: On March 2, 2020, Ms. Pedulla was granted 18,757 stock options. These options vest ratably over the first four anniversary dates of the grant date. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 01:16 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantCommon Stock | 2,912 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-20-000039 · wf-form4_158328455458567.xml · nonDerivative · entry 1 Pedulla Denise E · CIK 0001804602 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,988 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.